STOCK TITAN
  1. Home
  2. Sec-filings
  3. CMND
  4. [6-K] Clearmind Medicine Inc. Current Report (Foreign Issuer)

Clearmind Medicine (Nasdaq: CMND) cites U.S. momentum on psychedelic therapies

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Clearmind Medicine Inc., a clinical-stage psychedelic biotech, notes recent U.S. federal regulatory and inter-agency actions supporting development of psychedelic-based treatments for serious neuropsychiatric and addiction disorders.

The company develops novel, non-hallucinogenic, next-generation neuroplastogen-derived therapeutics, led by CMND-100 (MEAI / 5-MeO-AI), a non-hallucinogenic compound in FDA-cleared Phase I/IIa clinical trials for Alcohol Use Disorder at leading institutions including Yale University and Johns Hopkins.

Clearmind reports an intellectual property portfolio of nineteen patent families, including 32 granted patents, and aims to commercialize psychedelic-based compounds as regulated medicines, foods, or supplements. Its shares trade on Nasdaq under the symbol CMND.

Positive

  • None.

Negative

  • None.

Filing Explained

This Form 6-K furnishes a July 17 press release and incorporates its first and third paragraphs by reference into Clearmind’s identified Form F-3 and Form S-8 registration statements, updating those filings’ incorporated disclosure rather than reporting a securities transaction.

Patent families 19 Intellectual portfolio currently consists of nineteen patent families
Granted patents 32 Including 32 granted patents within its intellectual property portfolio
Lead candidate trial phase Phase I/IIa CMND-100 in FDA-cleared Phase I/IIa clinical trials for Alcohol Use Disorder
Fiscal year end October 31, 2025 Annual report on Form 20-F for the fiscal year ended October 31, 2025
neuroplastogen-derived therapeutics medical
"developing novel, non-hallucinogenic next-generation neuroplastogen-derived therapeutics for underserved"
Neuroplastogen-derived therapeutics are drugs or biological treatments developed from compounds that promote neuroplasticity — the brain’s ability to rewire and form new connections after injury or in response to learning. For investors, they matter because these therapies target underlying brain repair mechanisms rather than only masking symptoms, offering the potential for durable benefits in conditions like depression, stroke recovery, or neurodegeneration; if effective, they can create large, high-value markets similar to replacing a faulty bridge with a stronger one.
Alcohol Use Disorder (AUD) medical
"Phase I/IIa clinical trials for the treatment of Alcohol Use Disorder (AUD)"
A chronic medical condition in which a person repeatedly drinks alcohol in a way that they cannot control, continuing despite harm to their health, work or relationships; it ranges from risky drinking to severe dependence. Investors should care because AUD drives demand for treatments, public health spending, workplace productivity losses and regulatory attention—similar to how a persistent mechanical problem increases repair and operating costs, it creates long-term market and policy implications for healthcare, insurers and employers.
Phase I/IIa clinical trials medical
"a non-hallucinogenic compound in FDA-cleared Phase I/IIa clinical trials"
forward-looking statements regulatory
"This press release contains “forward-looking statements” within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Memoranda of Understanding regulatory
"new Memoranda of Understanding and collaborative initiatives involving the U.S."
A memorandum of understanding is a written, often non-binding agreement that outlines the basic terms and intentions of a potential deal or partnership before a formal contract is signed. For investors it signals that parties are negotiating in good faith—like a handshake on paper—so it can indicate progress and possible future value creation, but it does not guarantee the deal will happen or specify final legal obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What U.S. regulatory developments does Clearmind Medicine (CMND) highlight?
Clearmind highlights final FDA guidance on psychedelic clinical investigations, a planned public hearing on therapeutic psychedelic use, and new Memoranda of Understanding and collaborative initiatives among HHS, VA, FDA, NIDA, ARPA-H and HRSA supporting psychedelic-based treatments.

What is Clearmind Medicine's (CMND) lead drug candidate and trial status?
Clearmind's lead candidate is CMND-100 (MEAI / 5-MeO-AI), a non-hallucinogenic compound in FDA-cleared Phase I/IIa clinical trials for Alcohol Use Disorder at leading institutions, including Yale University and Johns Hopkins, targeting patients with significant unmet treatment needs.

What therapeutic focus does Clearmind Medicine (CMND) describe?
Clearmind describes itself as a clinical-stage neuroplastogens pharmaceutical biotech focused on discovering and developing non-hallucinogenic, second-generation neuroplastogen-derived therapeutics for widespread, underserved health problems, particularly Alcohol Use Disorder, addiction and weight management, with the goal of regulated medical and consumer commercialization.

What intellectual property portfolio does Clearmind Medicine (CMND) report?
Clearmind reports an intellectual property portfolio consisting of nineteen patent families, including 32 granted patents. The company also states it intends to seek additional patents when warranted and may opportunistically acquire further intellectual property to expand and strengthen its portfolio.

On which exchange are Clearmind Medicine (CMND) shares listed?
Clearmind states that its shares are listed for trading on Nasdaq under the symbol "CMND", providing U.S. public market access for investors interested in its clinical-stage, non-hallucinogenic psychedelic-based therapeutic development programs and intellectual property portfolio.
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: July 2026

 

Commission file number: 001-41557

 

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

 

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F ☐

 

 

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is the Registrant’s press release issued on July 17, 2026, titled “Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction”.

 

The first and third paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.    
99.1   Press release titled: “Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction”

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Clearmind Medicine, Inc.
  (Registrant)
     
Date: July 17, 2026 By: /s/ Adi Zuloff-Shani
  Name: Adi Zuloff-Shani
  Title: Chief Executive Officer

 

3

 

Exhibit 99.1

 

 

 

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction

 

Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, today noted the significant regulatory and inter-agency developments this week supporting the development of innovative treatments for serious neuropsychiatric and addiction disorders.

 

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated: “At a time when patients in the veterans community and the general population have too few treatment options for intractable neuropsychiatric and addiction disorders, we are grateful that Secretary Kennedy is looking to transform treatment opportunities through the expansion of new therapeutic approaches.”

 

This week’s developments include final FDA guidance on psychedelic clinical investigations, a planned public hearing on the therapeutic use of psychedelics, and new Memoranda of Understanding and collaborative initiatives involving the U.S. Department of Health and Human Services (HHS), Department of Veterans Affairs (VA), FDA, National Institute on Drug Abuse (NIDA), ARPA-H, and Health Resources and Services Administration (HRSA).

 

Clearmind Medicine is a clinical-stage psychedelic biotech company developing novel, non-hallucinogenic next-generation neuroplastogen-derived therapeutics for underserved medical needs. The Company’s lead candidate, CMND-100 (MEAI / 5-MeO-AI), is a non-hallucinogenic compound in FDA-cleared Phase I/IIa clinical trials for the treatment of Alcohol Use Disorder (AUD) at leading institutions including Yale University and Johns Hopkins.

 

About Clearmind Medicine Inc.

 

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

 

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

 

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

 

For further information, visit: https://www.clearmindmedicine.com or contact:

 

Investor Relations

 

invest@clearmindmedicine.com

 

www.Clearmindmedicine.com

 

Forward-Looking Statements:

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of MEAI and new therapeutic approaches, and the company’s intention to seek additional patents for its compounds whenever warranted and that it will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

 

Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain.

 

Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases